Biopharmaceutical Development Service

Resolian, formerly known as Alliance Pharma Inc. and Drug Development Solutions Ltd., excels at delivering specialized services in the analytical and bioanalytical space. Join CEO, Patrick Bennett, as he discusses the mission, vision, and values of the new name. Bennett provides a look into the strategy behind the company’s expansion into the Chinese market, describing the unique expertise housed within each of its four global laboratories, and how the company ensures synergy and harmonization between them.

This video was filmed at AAPS 2023 PharmSci 360.

Want the latest expert interviews, articles, webinars, virtual summits and more direct to your inbox? Become a SelectScience member for free today>>

Resolian specializes in providing comprehensive support for bioanalytical assay development, validation, and sample analysis, spanning the entire spectrum from early drug evaluation to clinical trials. The flexibility and agility of Resolian sets it apart, ensuring it can cater to specific demands. In this video, see how it is the right size and shape to adapt to the diverse needs of its clients and how it is committed to evolving and growing to better serve its partners in the world of pharmaceutical research.

This video was filmed at AAPS 2023 PharmSci 360.

Want the latest expert interviews, articles, webinars, virtual summits and more direct to your inbox? Become a SelectScience member for free today>>

Resolian (formerly Alliance Pharma Inc and Drug Development Solutions Ltd) is a global contract research organization (CRO) supporting pharmaceutical and biotech companies with specialized bioanalytical and analytical sciences solutions. Over 500 experts across the US, UK, and Australia, deliver quality results, ensuring the highest standard of regulatory compliance throughout the drug development continuum.

Resolian’s specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, drug metabolism/pharmacokinetics (DMPK), and CMC analytical and materials science. Dedicated laboratories equipped with state-of-the-art technology meet the needs of preclinical and clinical programs at any scale.

Michael Naughton, Senior Scientist in the Biologicals department within Drug Development Services at LGC, discusses how the company is implementing more sensitive assays to detect low abundance biomarkers and analytes, to meet the needs of the pharmaceutical industry. Hear how the Singulex Erenna® Immunoassay Platform from MilliporeSigma enables sensitive detection of analytes at below endogenous levels, providing a unique insight into health and disease states that can aid early decision making. A case study for IL-6 is presented.

James Howard, Scientist, Bioanalytical Sciences, Drug Development Services at LGC, explains how higher sensitivity in peptide bioanalysis is achieved through supercharging reagent, m-NBA (meta nitrobenzyl alcohol). Watch this video to find out how LGC develop LC-MS methods to overcome the challenges that come with the requirement of high sensitivity.

Find out how LGC are developing biopharmaceutical LC-MS methods to support preclinical and clinical studies. Kjetil Hansen, Scientist in the Bioanalysis department within Drug Development Services, discusses the benefits of using LC-MS methods over traditional immunoassay techniques, using the Waters SYNAPT G2 QTof and Xevo TQ-S.

In this video Sophia Christou, a scientist in the Bioanalysis department within Drug Development Services at LGC, explains how the company are working to improve validated analytical method transfer for sample analysis. Learn about the challenges associated with method transfer and the importance of communication of information between laboratories. A case study is presented to demonstrate the success of the company’s 5-day method transfer plan for three analytes.

The bridging assay aims to allow a full-length trimeric Spike protein from the COVID-19 virus to be used as both a capture and detection tool

Specific cross functional expertise in impurity analysis and contamination investigations

The acquisition of Toronto Research Chemicals brings wide breadth of synthetic and analytical chemistry capabilities

We bring you insights, tips and knowledge from 11 experts as they tackle biomarker research using diverse methods

Discover how LGC is overcoming the challenges of analyzing peptides with LC-MS

Learn about the process behind transferring a validated analytical method from one lab to another

Find out how new immunoassay techniques are being used to analyze samples from preclinical and clinical trials